KEYNOTE-024 , 5-year OS update: 1Lpembrolizumab(pembro) v/s platinum based chemo in pts with mNSCLC

KEYNOTE-024 , 5-year OS update: 1Lpembrolizumab(pembro) v/s platinum based chemo in pts with mNSCLC & PD-L1 (TPS)≥50%. Guidelines to manage immune related adverse events/ toxicities by Dr Maheboob Basade Medical Oncologist, Jaslok Hospital, Mumbai